Physiomics said it had been awarded a contract by a 'global top-10' pharmaceutical client, without being more specific. The project had a value of £70k and was expected to be completed during the company's current financial year. Chief executive Jim Millen said: 'We believe that the signing of agreements with three major pharmaceutical clients within the space of three months is a real sign of the confidence in our technology that is starting to build within the industry.' 'Our aim now will be to develop longer-term relationships with these major companies and to secure further pre-clinical and clinical projects.'
-0.10p (-1.67%)delayed 16:57PM